Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Home
>
Evidence Feed
VERI cancer hierarchy
Reset Filters
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
palbociclib + GDC-0077
Sensitive: B - Late Trials
Genentech Press Release - 5 days (New B)
palbociclib + GDC-0077
Sensitive
:
B
Genentech Press Release - 5d
palbociclib + GDC-0077
Sensitive: B - Late Trials
Genentech Press Release - 5 days
palbociclib + GDC-0077
Sensitive
:
B
Genentech Press Release - 5 days - (New B)
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
isatuximab-irfc
Sensitive: A1 - Approval
GlobeNewswire - 6 days (New B)
isatuximab-irfc
Sensitive
:
A1
GlobeNewswire - 6d
isatuximab-irfc
Sensitive: A1 - Approval
GlobeNewswire - 6 days
isatuximab-irfc
Sensitive
:
A1
GlobeNewswire - 6 days - (New B)
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 2 weeks (New A1)
lisocabtagene maraleucel
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 2wk
lisocabtagene maraleucel
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 2 weeks
lisocabtagene maraleucel
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 2 weeks - (New A1)
No biomarker
Squamous Cell Carcinoma of Head and Neck
No biomarker
Squamous Cell Carcinoma of Head and Neck
MCLA-158
Sensitive: B - Late Trials
GlobeNewswire - 2 weeks (New B)
MCLA-158
Sensitive
:
B
GlobeNewswire - 2wk
MCLA-158
Sensitive: B - Late Trials
GlobeNewswire - 2 weeks
MCLA-158
Sensitive
:
B
GlobeNewswire - 2 weeks - (New B)
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
NVL-655
Sensitive: B - Late Trials
PRNewswire - 2 weeks (New B)
NVL-655
Sensitive
:
B
PRNewswire - 2wk
NVL-655
Sensitive: B - Late Trials
PRNewswire - 2 weeks
NVL-655
Sensitive
:
B
PRNewswire - 2 weeks - (New B)
NRG1 fusion
Pancreatic Ductal Adenocarcinoma
NRG1 fusion
Pancreatic Ductal Adenocarcinoma
MCLA-128
Sensitive: B - Late Trials
GlobeNewswire - 3 weeks (New B)
MCLA-128
Sensitive
:
B
GlobeNewswire - 3wk
MCLA-128
Sensitive: B - Late Trials
GlobeNewswire - 3 weeks
MCLA-128
Sensitive
:
B
GlobeNewswire - 3 weeks - (New B)
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
IBI-343
Sensitive: B - Late Trials
PRNewswire - 3 weeks (New B)
IBI-343
Sensitive
:
B
PRNewswire - 3wk
IBI-343
Sensitive: B - Late Trials
PRNewswire - 3 weeks
IBI-343
Sensitive
:
B
PRNewswire - 3 weeks - (New B)
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
repotrectinib
Sensitive: A1 - Approval
Businesswire - 3 weeks (New A1)
repotrectinib
Sensitive
:
A1
Businesswire - 3wk
repotrectinib
Sensitive: A1 - Approval
Businesswire - 3 weeks
repotrectinib
Sensitive
:
A1
Businesswire - 3 weeks - (New A1)
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
goserelin acetate
Sensitive: A1 - Approval
Businesswire - 3 weeks (New A1)
goserelin acetate
Sensitive
:
A1
Businesswire - 3wk
goserelin acetate
Sensitive: A1 - Approval
Businesswire - 3 weeks
goserelin acetate
Sensitive
:
A1
Businesswire - 3 weeks - (New A1)
NRG1 fusion
Non Small Cell Lung Cancer
NRG1 fusion
Non Small Cell Lung Cancer
MCLA-128
Sensitive: B - Late Trials
GlobeNewswire - 3 weeks (New B)
MCLA-128
Sensitive
:
B
GlobeNewswire - 3wk
MCLA-128
Sensitive: B - Late Trials
GlobeNewswire - 3 weeks
MCLA-128
Sensitive
:
B
GlobeNewswire - 3 weeks - (New B)
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
EGFR T790M
Non Small Cell Lung Cancer
EGFR T790M
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
alectinib
Sensitive: A1 - Approval
alectinib
Sensitive
:
A1
alectinib
Sensitive: A1 - Approval
alectinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
KIT positive
Gastrointestinal Stromal Tumor
KIT positive
Gastrointestinal Stromal Tumor
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
margetuximab-cmkb
Sensitive: A1 - Approval
margetuximab-cmkb
Sensitive
:
A1
margetuximab-cmkb
Sensitive: A1 - Approval
margetuximab-cmkb
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
ALK fusion
Non Small Cell Lung Cancer
ALK fusion
Non Small Cell Lung Cancer
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
PDGFRA D842V
Gastrointestinal Stromal Tumor
PDGFRA D842V
Gastrointestinal Stromal Tumor
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login